🔎 Trials Near Me

Home › Amyotrophic Lateral Sclerosis › Arizona › Phoenix

Amyotrophic Lateral Sclerosis clinical trials in Phoenix, AZ

7 studies for Amyotrophic Lateral Sclerosis are looking for participants at sites in and around Phoenix (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

RecruitingPhase 1/2
  • St Joseph's Hospital and medical Center - Barrow Neurological Institute, Phoenix
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07287397

ASSESS ALL ALS Study

RecruitingObservational studyHealthy volunteers welcome
  • Barrow Neurological Institute, Phoenix
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06578195

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

RecruitingPhase 3
  • Barrow Neurological Institute, Phoenix
Ages 18 to 80 · All sexes · Updated Oct 27, 2026 · NCT07322003

EIM Via the Myolex mScan as an ALS Biomarker

RecruitingObservational study
  • Barrow Neurological Institute, Phoenix
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT06491732

Precise Robotically IMplanted Brain-Computer InterfacE

Recruiting
  • Barrow Neurological Institute, Phoenix
Ages 22 to 75 · All sexes · Updated Jan 9, 2026 · NCT06429735

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

RecruitingObservational studyHealthy volunteers welcome
  • Barrow Neurological Institute, Phoenix
Ages 18 and older · All sexes · Updated Nov 21, 2025 · NCT05137665

About Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, is a nerve disease that weakens muscles and gets worse over time. Learn how to manage symptoms.

More about Amyotrophic Lateral Sclerosis on MedlinePlus

Amyotrophic Lateral Sclerosis trials in other cities

Other studies in Phoenix

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.